Estudio experimental para la valoración de la cicatrización ósea con Ácido Zoledrónico en ratas Wistar

espanolAntecedentes y objetivos: El aumento del consumo de bifosfonatos en la sociedad actual, puede incrementar el riesgo de osteonecrosis mandibular. Se realizo este estudio para valorar si tras la extraccion dentaria, despues de la administracion subcutanea de acido zoledronico 7,5µg/Kg o 35 µg/Kg (Zometa®) en ratas Wistar, aparecen signos clinicos, radiograficos e histopatologicos de osteonecrosis y/o inflamacion. Lugar de realizacion: Centro Experimentacion Animal del Hospital de Defensa. Material y Metodos: Estudio experimental, in vitro, randomizado, intervencionista. Se utilizaron un total de 30 ratas Wistar (adultas, sanas), repartiendolas en tres grupos de 10 animales, segun sexo, grupo y farmaco: G0: Sin tratamiento con acido zoledronico. G1: Con tratamiento de acido zoledronico 7,5µg/Kg subcutaneo una dosis en los dias 1, 15 y 30. G2: Con tratamiento de acido zoledronico 35µg/Kg subcutaneo una dosis en los dias 1, 15 y 30. En todos los grupos se realizo exodoncia del primer molar inferior derecho el dia 30, sacrificando los animales a las cuatro semanas postextraccion, observando clinica, histologica y radiograficamente la aparicion de osteonecrosis e inflamacion. Resultados: Clinicamente se observaron en un 26,6% falta de epitelizacion compatible con signos precoces de osteonecrosis mandibular, segun criterios de la American Association of Oral Maxillofacial Surgeons (AAOMS). Esta es dosis dependiente en 3 animales de G1 (10%) y 5 animales de G2 (16,6%). Los resultados presentaron significacion estadistica p EnglishRecords and objectives: The increase of biphosphonates consumption on current society may increase the risk of mandibular osteonecrosis. This study was developed in order to value if, after dental extraction with a subcutaneous administration of zoledronic acid 7,5 µg/Kg or 35 µg/Kg (Zometa®) on Wistar rats, any clinic, radiographic or histopathological evidence of osteonecrosis or inflammation appear. Place of execution: Animal Experimentation Centre of the Hospital of Defence. Materials and methods: Experimental study, in vitro, randomized interventionist. A total amount of 30 Wistar rats were used (adults and healthy), divided into 3 groups of 10 animals according to sex, group and medicine. G0: no Zoledronic Acid treatment. G1: Zoledronic Acid treatment 7,5 µg/Kg subcutaneous, one dose on days 1, 15 and 30. G2: Zoledronic Acid treatment 35µg/Kg subcutaneous, one dose on days 1, 15 and 30. On all the groups an extraction of the lower right first molar was done on day 30, killing the animals four weeks post-extraction, observing clinically, histologically and radiographically the appearance of osteonecrosis and inflammation. Results: Clinically, a 26,6% showed a lack of epithelization compatible with early signs of mandibular osteonecrosis, according to the American Association of Oral Maxillofacial Surgeos (AAOMS) criteria. This is a dependent dose on 3 animals from G1 (10%) and 5 animals from G2 (16,6%). These results presented statistic signification p